30 Jun 2021
Xbrane Biopharma has carried out a directed share issue raising gross proceeds of SEK 380 millions
27 Jun 2021
Xlucane™ meets the primary endpoint in the pivotal Phase III trial with Xlucane™ – regulatory submission in EU and US planned for second half of 2021
16 May 2021
Xbrane announces ambition to generate positive operating cash flow monthly by late 2023/early 2024 and to initiate one new biosimilar development program per annum.
04 May 2021
Invitation to presentation of Xbrane Biopharma’s interim report January – March, 2021 on May 6, 2021.
15 Apr 2021
Xbrane Biopharma expands in-house Biosimilar development capabilities with new Biotech lab and invites participants to Virtual Capital Markets day on May 17.
15 Mar 2021
Xbrane strengthens the organization with the appointment of Erik Domines as General Counsel